Oracle (Redwood Shores, CA) announced the release of Remote Data Capture 4.6. The company collaborated with customer advisors to develop additional functions for the EDC application. The latest additions include scalability improvements, flexible branching to support complex trial design (including for oncology trials), access restriction capabilities, and patient management enhancements.
Remote Data Capture is integrated with the company’s clinical data management system, Oracle Clinical.
“R&D efficiency, clinical effectiveness and time to market continue to be the greatest challenges facing life sciences organizations today,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences, in a company press release. “Oracle Remote Data Capture 4.6 provides strong evidence of our unwavering commitment to helping clinical trial sponsors and CROs accelerate insights for better health, and will enable our customers to complete clinical trials significantly faster and much more cost effectively than ever before.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.